Clinical trials: Respiratory Tract Infection Viral
COVID-19, Post COVID-19
Virtual Physical Rehabilitation for Patients Living with Long COVID
The purpose of this study is to investigate whether a timely, virtual home-based physical rehabilitation program for patients living with long COVID can improve functional mobility compared to usual care.
- Conditions
- COVID-19, Post COVID-19, Long COVID
- Trial name
- NCT05298878
- Testing
- Intervention Group: Virtual home-based rehabilitation plus usual outpatient care
- Where
- 2 sites in Canada
- Volunteers
- 132 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Covid19
Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose
CombiVacS is a phase 2 randomized, adaptive trial developed to evaluate the immunogenicity of a dose of COMIRNATY after a previous single dose of VAXZEVRIA.
- Trial name
- CombiVacS (NCT05378191)
- Testing
- COMIRNATY
- Where
- 5 sites in Spain
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
SARS-CoV-2, COVID-19
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults.
- Trial name
- NCT05960097
- Testing
- CV0701 mRNA COVID-19 Vaccine (Low dose), CV0701 mRNA COVID-19 Vaccine (Medium dose), CV0701 mRNA COVID-19 Vaccine (High dose)
- Where
- 17 sites in United States, Australia
- Volunteers
- 692 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)
In this study the investigators are trying to understand how immune function declines in the elderly using annual influenza vaccinations as a model system. The longitudinal study began in 2007 and continued through early 2017.
- Trial name
- NCT01827462
- Testing
- Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Stanford University
Covid19
Covid-19 Virtual Recovery Study
The purpose of this study is to determine the effects of respiratory muscle training (RMT) and nasal breathing on patients who have been infected with the SARS-CoV2 virus and continue to have lingering symptoms.
- Trial name
- NCT04950725
- Testing
- Strength RMT, Strength RMT and nasal breathing, Endurance RMT
- Where
- United States
- Volunteers
- 2,268 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Influenza, Human
Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults
This is a safety and Immunogenicity first-in-human dose-ranging study of self-amplifying RNA Seasonal Influenza Vaccine (ARCT-2138) in adults.
- Trial name
- NCT06125691
- Testing
- ARCT-2138, Licensed Quadrivalent Vaccine for younger adults, Licensed Quadrivalent Vaccine for older adults
- Where
- 2 sites in Australia
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Mild Cognitive Impairment, Dementia
Cognitive Outcomes During COVID-19 confiNemeNt in Elderly and Their Caregivers Using Technologies for DEMentia
Coronavirus disease 2019 has forced worldwide the implementation of unprecedented restrictions to control its rapid spread and mitigate its impact.
- Trial name
- CONNECTDEM (NCT04385797)
- Testing
- Telephone interview
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Vaccine Refusal, COVID-19
Exploring the Effect of Video Interventions on Intentions for Continued COVID-19 Vaccination
While COVID-19 vaccine uptake has generally been high in Canada, with 83.4% of the total population having received the first two doses (i.e., primary series), additional "booster" uptake has been slower, especially among young…
- Trial name
- NCT05808413
- Testing
- Informational Video, Altruistic Video, Individualistic Video
- Where
- Canada
- Volunteers
- 3,567 people, healthy volunteers welcome
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Sars-CoV2
Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19
No optimal antiviral intervention has been yet validated to treat COVID-19 disease. Comorbidities, such as older age, obesity, diabetes, history of cardiovascular diseases are associated with poor prognosis.
- Trial name
- HYdILIC (NCT04372082)
- Testing
- Standard of care (SOC), Hydroxychloroquine, Association of diltiazem and niclosamide
- Sponsor
- University Hospital, Lille
COVID-19, Immunologic Factors
Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine.
A two-stage trial will involve healthy volunteers. The first stage is open trial, and the second stage is a double-blind trial with randomization of volunteers into three groups.
- Conditions
- COVID-19, Immunologic Factors, Coronavirus Infections, Respiratory Tract Infections
- Trial name
- NCT05156723
- Testing
- Subunit recombinant vaccine for the prevention of coronavirus infection
- Where
- 3 sites in Russia
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Kidney Failure, Chronic, Covid19
Assessment of Immune Response After Vaccination Against COVID-19 in Patients Treated With Renal Replacement Therapy
Chronically dialyzed patients and kidney transplant recipients have been identified as particularly vulnerable to SARS-CoV-2 infection due to unavoidable exposure.
- Conditions
- Kidney Failure, Chronic, Covid19, Vaccine Reaction, Vaccine Adverse Reaction
- Trial name
- COViNEPH-1 (NCT04905862)
- Testing
- Immune response, Solicited common and expected adverse reactions shortly following vaccination (reactogenicity), use of antipyretic or pain medications and unsolicited adverse events and serious adverse events
- Where
- 4 sites in Poland
- Volunteers
- 180 people
- Sponsor
- Medical University of Gdansk
COVID-19
Pulmonary and Extrapulmonary Impairments in Patients With Post COVID-19
Pulmonary involvement and fibrosis could be seen in patients after COVID-19. Especially diffusion capacity, pulmonary function, exercise capacity and muscle strength have decreased in patients with COVID-19.
- Trial name
- NCT05381727
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Gazi University
Influenza
Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years
The study will evaluate the immune response and the tolerability of the influenza vaccine administered in children aged 6-13 years old.
- Trial name
- NCT00372255
- Testing
- Influsplit SSW® 2005/2006
- Where
- 18 sites in Germany
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
The aim of this study is to evaluate the safety and immunogenicity of Fluzone® Quadrivalent vaccine in participants aged 6 months to < 9 years at enrollment, divided into 2 age strata (6 months to < 36 months and 3 years to < 9…
- Trial name
- NCT01946425
- Testing
- Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza (Pandemic)
A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant
This is a randomized, observer-blinded, placebo-controlled trial in adults 18 to 64 years old. Randomization will be stratified by age (18 to 49 years and 50 to 64 years) and by prior influenza immunization within the past three…
- Trial name
- NCT02078674
- Testing
- Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant
- Where
- 5 sites in United States
- Volunteers
- 610 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza Immunization, Healthy Volunteers
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
This was a phase IV, multi-center, open-label study. The study collected serum samples from children 6 months to less than (<) 9 years of age who received Fluzone Quadrivalent vaccine and adults greater than or equal to (>=) 65…
- Trial name
- NCT05050318
- Testing
- Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Covid19
COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020
The management of the Grand Hôpital de Charleroi hospital authorized the performance of a serology for each member of the establishment's staff in order to better characterize the proportion of its employees who have already been…
- Trial name
- NCT04723290
- Testing
- Serological tests for SARS Cov-2
- Where
- Belgium
- Volunteers
- 2,817 people, healthy volunteers welcome
- Sponsor
- Grand Hôpital de Charleroi
SARS CoV 2 Infection
Rutgers Pilot for PREDICT- Patient POC Test
A pilot study was initiated to assess feasibility of testing asymptomatic dental patients presenting to the Oral Medicine Clinic at Rutgers School of Dental Medicine for SARS-CoV-2 viral antigen using a point-of-care (POC) Rapid…
- Trial name
- NCT05612724
- Testing
- Testing for SARS CoV2 Antigen
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Common Cold, Pharyngitis
Alleviation of Common Cold Symptoms
Upper respiratory infections (URIs) have long posed a significant burden to the US healthcare system. Well before the coronavirus disease of 2019 (COVID-19) pandemic they have been among the most common acute outpatient…
- Conditions
- Common Cold, Pharyngitis, Fever, Congestion
- Trial name
- NCT06106880
- Testing
- Wintergreen Throat Spray and Aspirin Tablet
- Where
- 6 sites in United States
- Volunteers
- 157 people
- Sponsor
- Applied Biological Laboratories Inc
Covid19
Safety & Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid-19 Patients
COVID-19, caused by the novel Severe Acute Respiratory Syndrome Corona Virus 2 (SARSCoV-2), has become a global pandemic. Fortunately, most of the COVID-19 cases confirmed are categorized as mild for whom home- based symptomatic…
- Trial name
- IVCOM (NCT04768179)
- Testing
- 3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)
- Volunteers
- 490 people
- Sponsor
- Makerere University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.